Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will focus on its expanded pipeline of antibiotics, represented through several presentations, during IDWeek 2013 being held October 2-6 in San Francisco. Presentations will feature the company’s development of antibiotics for serious infections caused by multidrug-resistant bacteria. Several presentations will also highlight the marketed antibiotic CUBICIN® (daptomycin for injection).
Presentations at IDWeek will focus on the company’s late stage candidates ceftolozane/tazobactam (formerly CXA-201) being studied for the treatment of Gram-negative bacteria and surotomycin (formerly CB-183,815) being studied for the treatment of diarrhea caused by Clostridium difficile (C. difficile), categorized as an urgent threat in the recent U.S. Centers for Disease Control and Prevention (CDC) report “Antibiotic Resistant Threats in the United States, 2013.” Presentations will also feature tedizolid phosphate, a once daily, I.V. or orally administered oxazolidinone being developed for the treatment of serious Gram-positive skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In addition, Cubist expects to begin trials with tedizolid phosphate in gram-positive lung infections later this year. Cubist has added tedizolid to its pipeline through the recent acquisition of Trius Therapeutics. All of these candidates have been granted Fast Track status, pursuant to the GAIN Act, by the U.S. Food and Drug Administration (FDA) for their respective Qualified Infectious Disease Product (QIDP) indications.
“With the recent acquisition of Trius, Cubist is making significant traction towards meeting the IDSA challenge to industry and policy makers to develop and approve 10 new antibiotics by 2020. We are keenly focused on combatting growing antibacterial resistance and rising hospital-acquired infections,” said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist Pharmaceuticals. “Our presentations will focus on our expanded pipeline, which includes antibiotics being developed to address pathogens contributing to the escalating global public health threat. During IDWeek we are also marking the 10 year anniversary of CUBICIN, which was developed and launched by Cubist.”